Background

Stem cell therapy has been proven to rescue intestinal injury and stimulate intestinal regeneration in necrotizing enterocolitis (NEC). Specifically, stem cells derived from amniotic fluid (AFSCs) and mesenchymal stem cells (MSCs) derived from bone marrow have shown promising results in the treatment of experimental NEC. This study aims to examine the effects of AFSCs and MSCs on the prevention of intestinal injury during experimental NEC.

Methods

Supernatants from AFSC and MSC cultures were collected to perform proteomic analysis. Prior to NEC induction, mice received intraperitoneal injections of phosphate-buffered saline (PBS), 2 × 10⁶ AFSCs, or 2 × 10⁶ MSCs.

Results

We found that AFSCs grew faster than MSCs. Proteomic analysis indicated that AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. Administering AFSCs before NEC induction decreased NEC severity and mucosal inflammation. Intestinal proliferation and endogenous stem cell activation were increased after AFSC administration. However, administering MSCs before NEC induction had no beneficial effects.

Conclusions

This study demonstrated that AFSCs and MSCs have different protein release profiles. AFSCs can potentially be used as a preventative strategy for neonates at risk of NEC, while MSCs cannot be used.

Impact

• AFSCs and MSCs have distinct protein secretory profiles, and AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation.

• AFSCs are unique in transiently enhancing healthy intestinal epithelial cell growth, which offers protection against the development of experimental NEC.

• The prevention of NEC via the administration of AFSCs should be evaluated in infants at great risk of developing NEC or in infants with early signs of NEC.

中文翻译：

---

羊水干细胞给药可预防坏死性小肠结肠炎引起的上皮损伤

背景

干细胞疗法已被证明可以挽救坏死性小肠结肠炎 (NEC) 患者的肠道损伤并刺激肠道再生。具体而言，源自羊水 (AFSC) 的干细胞和源自骨髓的间充质干细胞 (MSC) 在治疗实验性 NEC 方面显示出可喜的结果。本研究旨在检查 AFSCs 和 MSCs 在实验性 NEC 期间预防肠道损伤的作用。

方法

收集来自 AFSC 和 MSC 培养物的上清液以进行蛋白质组学分析。^{在诱导 NEC 之前，小鼠接受了磷酸盐缓冲盐水 (PBS)、2 × 10 6 个}AFSC 或 2 × 10 ^{6 个}MSC的腹膜内注射。

结果

我们发现 AFSC 比 MSC 生长得更快。蛋白质组学分析表明，AFSCs 主要参与细胞发育和生长，而 MSCs 参与免疫调节。在 NEC 诱导之前给予 AFSC 可降低 NEC 的严重程度和粘膜炎症。AFSC 给药后肠道增殖和内源性干细胞活化增加。然而，在 NEC 诱导之前施用 MSCs 没有任何有益效果。

结论

该研究表明 AFSC 和 MSC 具有不同的蛋白质释放曲线。AFSCs 可能被用作有 NEC 风险的新生儿的预防策略，而 MSCs 则不能使用。

影响

• AFSCs 和 MSCs 具有不同的蛋白质分泌谱，AFSCs 主要参与细胞发育和生长，而 MSCs 参与免疫调节。

• AFSC 在瞬时增强健康肠上皮细胞生长方面是独一无二的，这可以防止实验性 NEC 的发展。

• 应在极有可能发展为 NEC 的婴儿或有 NEC 早期迹象的婴儿中评估通过施用 AFSC 预防 NEC 的效果。